Introduced for the 1962 model year, the Chevy II/Nova was Chevrolet's response to the Ford Falcon, which outsold the similarly sized but rear-engined Corvair. Initially powered by small-displacement ...

GM recalls nearly 600,000 vehicles for L87 V8 engine failures after 1,000+ complaints. Multiple lawsuits now consolidated and the class action lawsuit is set to begin; plaintiffs claim GM's repair ...

General Motors will be one of the few automakers to ditch support for Apple CarPlay and Android Auto. Apple CarPlay and Android Auto are screen-mirroring apps that let you interact with many of the ...

3rd January 2025: We added new Type Soul codes. Type Soul is a Roblox game based on the popular anime series Bleach. The experience originally launched around the time that Part 2 of the Thousand Year ...

GM has released a Service Update through the National Highway Traffic Safety Administration (NHTSA) for the 2020-2022 Chevy Bolt EV and Chevy Bolt EUV. Service Update N232421261 addresses a condition ...

Tom Bowen is a senior editor who loves adventure games and RPGs. He's been playing video games for several decades now and writing about them professionally since 2020. Although he dabbles in news and ...

General Motors is recalling nearly 600,000 Chevrolet, Cadillac and GMC vehicles due to engine issues that could cause damage or total failure. According to a notice first reported to the National ...

During a fireside chat with Meta CEO Mark Zuckerberg at Meta’s LlamaCon conference on Tuesday, Microsoft CEO Satya Nadella said that 20% to 30% of code inside the company’s repositories was “written ...

As one of the world's biggest car companies, Chevrolet sells an enormous number of vehicles every year – 1,745,809 in the United States in 2024 alone. Currently offering 24 models, Chevrolet offers a ...

Artur is a copywriter and SEO specialist, as well as a small business owner. In his free time, he loves to play computer games and is glad that he was able to connect his professional career with his ...

Ropeginterferon alfa-2b-njft (P1101) achieved durable hematologic responses in ET patients with a manageable safety profile, outperforming anagrelide in the SURPASS-ET trial. P1101 showed a ...

Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...